Evidence map›Paper›PMID 35417045›Full record

ArticleMolecular carcinogenesis2022

Mefloquine induces ER stress and apoptosis in BRAFi-resistant A375-BRAF

Jana Jandova, Sophia L Park, Mandi J Corenblum, Lalitha Madhavan, Jeremy A Snell, Liliana Rounds, Georg T Wondrak

Open access · greenAbstract read
In one paragraph

Article in Molecular carcinogenesis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jana JandovaDepartment of Pharmacology and Toxicology, RK Coit College of Pharmacy & The University of Arizona Cancer Center, University of Arizona, Tucson, Arizona, USA.
Sophia L ParkDepartment of Pharmacology and Toxicology, RK Coit College of Pharmacy & The University of Arizona Cancer Center, University of Arizona, Tucson, Arizona, USA.
Mandi J CorenblumDepartment of Neurology, Evelyn F McKnight Brain Institute and BIO5 Institute, University of Arizona, Tucson, Arizona, USA.
Lalitha MadhavanDepartment of Neurology, Evelyn F McKnight Brain Institute and BIO5 Institute, University of Arizona, Tucson, Arizona, USA.
Jeremy A SnellDepartment of Pharmacology and Toxicology, RK Coit College of Pharmacy & The University of Arizona Cancer Center, University of Arizona, Tucson, Arizona, USA.
Liliana RoundsDepartment of Pharmacology and Toxicology, RK Coit College of Pharmacy & The University of Arizona Cancer Center, University of Arizona, Tucson, Arizona, USA.
Georg T WondrakDepartment of Pharmacology and Toxicology, RK Coit College of Pharmacy & The University of Arizona Cancer Center, University of Arizona, Tucson, Arizona, USA.
University of Arizona · US

Funding

VITAMIN AP30CA023074 · NCI · UNIVERSITY OF ARIZONA · PI Dan Theodorescu · 1985 to 2026
$110.2M
SOUTHWEST ENVIRONMENTAL HEALTH SCIENCES CENTERP30ES006694 · NIEHS · UNIVERSITY OF ARIZONA · PI George S Watts · 1994 to 2026
$36.7M
Training in Environmental Toxicology of Human DiseaseT32ES007091 · NIEHS · UNIVERSITY OF ARIZONA · PI Nathan J Cherrington · 1985 to 2026
$10.7M
Targeted Prevention for Non-Melanoma Skin CancerP01CA229112 · NCI · UNIVERSITY OF ARIZONA · PI MANSOUR, HEIDI M. · 2019 to 2023
$7.1M
Repurposing Clinical ACT Antimalarials for Experimental Melanoma InterventionR01CA229418 · NCI · UNIVERSITY OF ARIZONA · PI WONDRAK, GEORG T · 2019 to 2023
$1.7M
Exploring the role of HOCI in skin photodamage, immunosuppression, and carcinogenesisR21ES029579 · NIEHS · UNIVERSITY OF ARIZONA · PI WONDRAK, GEORG T · 2019 to 2020
$409k
NCI NIH HHS P01 CA229112NCI NIH HHS P30 CA023074NCI NIH HHS R01 CA229418NIEHS NIH HHS P30 ES006694NIEHS NIH HHS R21 ES029579NIEHS NIH HHS T32 ES007091
6 · The paper itself

Abstract

Molecularly targeted therapeutics have revolutionized the treatment of BRAF

Indexed as

AntimalarialsBrain NeoplasmsMelanomaAnimalsApoptosisCell Line, TumorCutaneous Malignant MelanomaDisease Models, AnimalDrug Resistance, NeoplasmGTP PhosphohydrolasesHumansMefloquineMembrane ProteinsMiceProtein Kinase InhibitorsProto-Oncogene Proteins B-rafAntimalarialsBRAF protein, humanGTP PhosphohydrolasesMefloquineMembrane ProteinsNRAS protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins B-rafantimalarial chemotherapeuticsbrain metastasesER stressgene expression array analysismalignant melanomamefloquineNRAS-driven BRAFi-resistance

Identifiers

PMID35417045
PMCPMC9133119
OpenAlexW4223482404

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.